AnaptysBio Advances Spin-Off Amid Strong Jemperli Sales, But Core Risks Unchanged

What happened

AnaptysBio announced progress on its planned separation, with the spin-off of biopharma operations into First Tracks Biotherapeutics on track for Q2 2026, potentially as early as late April. The company reported fourth-quarter and full-year 2025 financial results, highlighting GSK's Jemperli sales growth to $343 million in Q4, implying a ~$1.4 billion annualized run rate. However, this royalty stream is financially encumbered by a monetization agreement that renders most reported revenue non-cash, with a 30.5% effective interest rate, complicating cash conversion. The ongoing legal dispute with GSK/Tesaro over royalty payments, with a trial scheduled for July 2026, remains a critical overhang that could alter economics. Despite operational momentum, the equity's value is still hostage to unresolved legal and separation milestones, with cash reserves of $311 million providing limited downside protection.

Implication

The accelerated separation timeline may reduce the conglomerate discount, but execution risks are high, and capitalization of the biotech entity could strain resources. Jemperli's strong sales support royalty tier step-ups, but the monetization structure means GAAP revenue does not translate to clean cash, limiting near-term financial flexibility. The legal dispute over royalty payments, with a trial in July 2026, poses a binary risk that could materially impact the valuation anchor, requiring close monitoring. Cash reserves of $311 million offer a runway, but funding the separation and pipeline advancements may necessitate additional capital, potentially leading to dilution. Overall, investors are advised to wait for clarity on the $75M milestone accrual and legal developments before committing capital, as these are pivotal for de-risking the investment.

Thesis delta

The update reaffirms the separation plan and Jemperli sales strength, but it does not address the key uncertainties around the $75M milestone accrual or legal risks identified in the DeepValue report. The thesis remains unchanged: investors should prioritize de-risking these items over near-term optimism, maintaining a 'WAIT' rating until clearer signals emerge on cash conversion and legal outcomes.